Invasive mucinous adenocarcinoma is a distinct histologic variant of lung adenocarcinoma that is characterized by tall columnar cells with basally oriented nuclei and intracytoplasmic mucin and was formerly referred to as mucinous bronchioloalveolar carcinoma. In most cases, these tumors characteristically display lepidic growth. The clinical presentation of mucinous adenocarcinoma may vary from a small nodular lesion to lobar/multilobar consolidation, and it is not uncommon to encounter multicentric dissemination at presentation, probably reflecting aT-stage subgroups. In multivariate analysis, the size of invasive patterns (p = 0.020), pleural invasion (p < 0.001), and vascular invasion (p = 0.048) were independent predictors of recurrence, whereas total size failed to achieve statistical significance (p = 0.121). Conclusions: This study provides a rationale for histologic risk stratification in pulmonary MA based on the extent of invasive growth patterns with refined criteria for invasion.
were non-mucinous adenocarcinomas, the prognostic relevance and the prevalence of lepidic pattern have not been documented for mucinous adenocarcinomas. Furthermore, detailed histomorphologic analysis of the non-lepidic pattern in mucinous adenocarcinomas has not been performed.

To clarify the prognostic significance of lepidic and non-lepidic invasive patterns, we evaluated a series of resected pulmonary mucinous adenocarcinomas with refined criteria for invasion and correlated invasive patterns with clinical outcome.

**MATERIALS AND METHODS**

**Patient identification**

Between 1995 and 2013, we identified 4,119 cases of surgically resected lung adenocarcinoma at Samsung Medical Center, Korea. We initially collected 317 cases diagnosed as mucinous adenocarcinoma, as well as cases of mucinous bronchioloalveolar carcinoma, from our pathology reports. On pathologic review, the cytomorphologic features of these tumors were rigorously examined. Tall columnar or goblet cell morphology showing characteristic

---

**Fig. 1.** Examples of lepidic pattern and non-distorted acini (pattern 1). (A–F) Low-powered (A, C, E) and high-powered (B, D, F) view. (A, B) Typical lepidic pattern showing strips of tumor cells clinging to alveolar walls. (C, D) In areas where the stroma is increased, acinar structures (pattern 1) are formed without alteration of cytomorphologic features. (E, F) Densely spaced, bland acinar structures (pattern 1). The stroma is elastotic, not desmoplastic.

(Continued to the next page)
lepidic growth at the tumor periphery was set as the histologic inclusion criteria in this study. Mixed mucinous and non-mucinous tumors with extracellular rather than intracellular mucin, colloid adenocarcinomas predominantly composed of dissecting mucin pools, and enteric adenocarcinomas were excluded. Cases with a history of preoperative treatment and synchronous primary lung cancers were also excluded. Nine cases were excluded because they had multicentric disease at presentation and were resected for diagnostic purposes. Cases showing solid signet ring cells and a cribriform and tubulopapillary pattern were suspected to be anaplastic lymphoma kinase (ALK)–rearranged tumors, and 12 cases were excluded after subsequent ALK immunohistochemical staining for confirmation. Finally, a total of 188 cases of surgically treated mucinous adenocarcinoma were evaluated. This study was approved by the Samsung Medical Center Institutional Review Board (file No. 2016-03-055).

Histologic review

All tumors were sectioned and stained in a routine manner and reviewed by two pathologists (S.H. and J.H.) who were blinded to patient outcome. The mean number of reviewed slides was 4.43 per case, corresponding to 1.25 per centimeter of tumor when the total number of reviewed slides was divided by the sum of the greatest dimensions. Lepidic pattern was defined as tumor growth along preexisting alveolar walls, as previously described (Fig. 1A, B). For non-lepidic patterns, it was difficult to apply the conventional architectural patterns of non-mucinous adenocarcinomas to mucinous adenocarcinomas. Instead, we categorized non-lepidic patterns into three different patterns based on cytomorphologic, architectural and stromal characteristics compared to the lepidic pattern.

Pattern 1 was assigned to areas showing bland, non-distorted acinar structures with increased stroma compared to the lepidic pattern (Fig. 1C–F). Cytomorphologic alteration compared to the lepidic pattern was not apparent, with retention of tall columnar cells with preserved nuclear polarity. Architectural distortion was minimal to the extent that the pattern resembled uninvolved alveolar spaces. Increased stroma, which was the only feature distinguishing this pattern from the lepidic pattern, was almost always elastotic, not desmoplastic. Indeed, this pattern was often more reminiscent of lepidic pattern than a true invasive acinar pattern. Presence of the central scar itself did not permit exclusion of this pattern, unless accompanied by cytomorphologic or architectural changes or prominent desmoplasia.

Pattern 2 was assigned to areas showing invasion into the stroma, as evidenced by cytomorphologic alteration, architectural distortion and stromal desmoplasia (Fig. 2A–D). The tumor cells displayed an irregular, jagged, or anastomosing architecture that was clearly distinguishable from normal alveolar structure. Less columnar cytomorphology with loss of nuclear polarity was typically seen in this pattern. Infiltrating single cells with eosinophilic cytoplasm or fused glands with paler cytoplasm were often observed.

Pattern 3 was assigned to areas showing invasion into alveolar spaces. This pattern typically arose in the background of the lepidic pattern and showed proliferation toward alveolar spaces (Fig. 2E, F). A similar pattern in non-mucinous adenocarcinoma has been referred to as “low papillary structure” by Fukutomi et al. Similar to papillary and micropapillary pattern in non-mucinous adenocarcinomas, this pattern did not require desmoplastic stroma. Excess proliferation into airspaces frequently caused tumor cells to float within airspaces. When these floating tumor cells were arranged as single cells, ring-like structures, or tight clusters, which were distinguishable from tumor branches at-
tached to the alveolar wall, they were further subcategorized as a micropapillary pattern (Fig. 2F).

Each pattern was recorded in terms of percentage, except for pattern 1. A clear distinction between pattern 1 and the lepidic pattern was not always feasible, since pattern 1 lacked cytomorphologic changes. Furthermore, since acinar structures in pattern 1 were devoid of any features of invasion such as desmoplasia or cytomorphologic atypia as seen in acinar pattern of invasion in non-mucinous adenocarcinoma, we postulated that pattern 1 might be a morphologic spectrum that still represents lepidic growth (Fig. 1G, H), or at least a growth pattern that is related to indolent biologic behavior as a lepidic pattern. We therefore regarded lepidic and pattern 1 as non-invasive patterns, whereas patterns 2 and 3 were considered unequivocally invasive patterns.

To measure the size of invasive patterns, the proportions of patterns 2 and 3 were combined. Since the invasive patterns were frequently
multifocal, the size of invasion was calculated by multiplying the percentage by the total size in the majority of cases. The size of confluent invasion measured in a single slide was adopted only when it exceeded the calculated value. According to the size of invasive pattern, conventional T staging was adjusted (aT) as follows: aTis, no invasion; aT1mi, minimal (≤ 5 mm) invasion; aT1a, > 5 mm, ≤ 1 cm invasion; aT1a2, > 1 cm, ≤ 2 cm invasion; aT1b, > 2 cm, ≤ 3 cm invasion; aT2a, > 3 cm, ≤ 5 cm invasion or visceral pleural invasion (PL1-2); aT2b, > 5 cm, ≤ 7 cm invasion; aT3, > 7 cm invasion or satellite tumor nodule in the same lobe or parietal pleural invasion (PL3); and aT4, satellite tumor nodule in a different ipsilateral lobe. Conventional TNM staging and Table 1. Correlation of clinicopathologic characteristics with adjusted T stage (aT*)

| Factor                  | All patients | aTis/1mi* | aT1a/1b* | aT2a/3/4* | p-value |
|-------------------------|--------------|----------|----------|-----------|---------|
| Total                   | 188 (100)    | 112 (59.6) | 41 (21.8) | 35 (18.6) |         |
| Age (yr)                |              |          |          |           | .004    |
| <65                     | 119 (63.3)   | 81 (72.3) | 18 (43.9) | 20 (57.1) |         |
| ≥65                     | 69 (36.7)    | 31 (27.7) | 23 (56.1) | 15 (42.9) |         |
| Sex                     |              |          |          |           | .003    |
| Female                  | 106 (56.4)   | 74 (66.1) | 19 (46.3) | 13 (37.1) |         |
| Male                    | 82 (43.6)    | 38 (33.9) | 22 (53.7) | 22 (62.9) |         |
| Smoking                 |              |          |          |           | <.001   |
| Never                   | 117 (62.2)   | 82 (73.2) | 21 (51.2) | 14 (40.0) |         |
| Ever                    | 71 (37.8)    | 30 (26.8) | 20 (48.8) | 21 (60.0) |         |
| Nuclear atypia          |              |          |          |           | <.001   |
| Mild                    | 105 (55.9)   | 89 (79.5) | 14 (34.1) | 4 (11.4)  |         |
| Moderate                | 59 (31.4)    | 22 (19.6) | 18 (43.9) | 17 (48.6) |         |
| Severe                  | 24 (12.8)    | 1 (0.9)   | 9 (22.0)  | 14 (40.0) |         |
| Micropapillary          |              |          |          |           | <.001   |
| 0%                      | 128 (68.1)   | 101 (80.2) | 20 (48.8) | 7 (20.0)  |         |
| 1%–9%                   | 25 (13.3)    | 10 (8.9)  | 8 (19.5)  | 7 (20.0)  |         |
| ≥10%                    | 35 (18.6)    | 1 (0.9)   | 13 (31.7) | 21 (60.0) |         |
| Aerogenous spread       |              |          |          |           | <.001   |
| Absent                  | 136 (72.3)   | 99 (88.4) | 25 (61.0) | 12 (34.3) |         |
| Present                 | 52 (27.7)    | 13 (11.6) | 16 (39.0) | 23 (65.7) |         |
| Vascular invasion       |              |          |          |           | <.001   |
| Absent                  | 172 (91.5)   | 112 (100) | 33 (80.5) | 27 (77.1) |         |
| Present                 | 16 (8.5)     | 0        | 8 (19.5)  | 8 (22.9)  |         |
| Necrosis                |              |          |          |           | <.001   |
| Absent                  | 170 (81.4)   | 111 (99.1) | 37 (90.2) | 22 (62.8) |         |
| Present                 | 18 (8.6)     | 1 (0.9)   | 4 (9.8)   | 13 (37.1) |         |
| Neutrophils             |              |          |          |           | <.001   |
| Absent                  | 118 (62.8)   | 97 (86.6) | 10 (24.4) | 11 (31.4) |         |
| Present                 | 70 (37.2)    | 15 (13.4) | 31 (75.6) | 24 (68.6) |         |
| KRAS (n=59)             |              |          |          |           | .014    |
| Wild                    | 34 (57.6)    | 23 (74.2) | 2 (25.0)  | 9 (45.0)  |         |
| Mutated                 | 25 (42.4)    | 8 (25.8)  | 6 (75.0)  | 11 (55.0) |         |
| T stage                 |              |          |          |           | <.001   |
| 1a                      | 61 (32.4)    | 57 (69.0) | 4 (9.8)   | 0         |         |
| 1b                      | 42 (22.3)    | 29 (25.9) | 13 (31.7) | 0         |         |
| 2a                      | 49 (26.1)    | 21 (18.8) | 18 (43.9) | 10 (28.6) |         |
| 2b                      | 18 (9.6)     | 3 (2.7)   | 5 (12.2)  | 10 (28.6) |         |
| 3/4*                    | 18 (9.6)     | 2 (1.8)   | 1 (2.4)   | 15 (42.9) |         |
| N stage                 |              |          |          |           | <.001   |
| 0                       | 177 (94.1)   | 111 (99.1) | 36 (92.7) | 28 (80.0) |         |
| 1/2                     | 11 (5.9)     | 1 (0.9)   | 3 (7.3)   | 7 (20.0)  |         |

Values are presented as number (%).
*Adjusted T stage (aT): aTis, no invasion; aT1mi, minimal (≤ 5 mm) invasion; aT1a, > 5 mm, ≤ 1 cm invasion; aT1a2, > 1 cm, ≤ 2 cm invasion; aT1b, > 2 cm, ≤ 3 cm invasion; aT2a, > 3 cm, ≤ 5 cm invasion or visceral pleural invasion (PL1-2); aT2b, > 5 cm, ≤ 7 cm invasion; aT3, > 7 cm invasion or satellite tumor nodule in the same lobe or parietal pleural invasion (PL3); aT4, satellite tumor nodule in a different ipsilateral lobe; *One T4 case was included.
pleural invasion were assessed according to the seventh American Joint Committee on Cancer TNM staging manual.18

Nuclear atypia was measured in the area showing the highest degree of atypia, and graded as follows: “mild,” small, slightly irregular nuclei with no nucleoli; “moderate,” intermediate-sized, moderately irregular nuclei with small nucleoli; and “severe,” large, markedly irregular nuclei with vesicular chromatin and prominent nucleoli. AS was considered present when tumor cells were present beyond 2 mm from the edge of the main mass. This included discontinuous tumor islands in lepidic pattern as well as single cells, micropapillary, or ring-like structures, termed tumor spread through air spaces in recent studies.19,20 Vascular invasion, either lymphatic or venous, and tumor necrosis were examined. Intra-alveolar accumulation of neutrophils, which was previously reported to be related with adverse outcome in mucinous adenocarcinoma, was also evaluated.21,22

EGFR and KRAS mutation, and ALK rearrangement

EGFR gene mutation was detected by real-time polymerase chain reaction with PNA clamping using the PNA-Clamp EGFR Mutation Detection kit (PANAGENE, Inc., Daejeon, Korea) or by direct sequencing of exons 18, 19, 20, and 21, as previously described.23 KRAS gene mutation was detected by direct sequencing of codons 12 and 13 in exon 2 and codon 61 in exon 3, as previously described.23 Immunohistochemical staining for ALK protein (1:30, clone 5A4, Novocastra, Newcastle upon Tyne, UK) was used to detect ALK gene rearrangement, and diffuse moderate to strong cytoplasmic reactivity was regarded as positive, as previously described.23

Statistical analysis

The correlations between clinicopathologic variables and adjusted tumor (aT) stage were assessed by Fisher exact test and chi-square test. Disease-free survival (DFS) was evaluated using the Kaplan-Meier method, and the log-rank test was used for comparison. Multivariate survival analysis was performed using the Cox proportional hazards model. All statistical analyses were performed using SPSS Statistics ver. 19.0 (IBM Corp., Armonk, NY, USA).

Table 2. Correlation of clinicopathologic variables with DFS

| Factor               | No. (%) | 5-year DFS (%) | p-value |
|----------------------|---------|----------------|---------|
| Age (yr)             |         |                |         |
| <65                  | 119 (63.3) | 80.0          | .097    |
| ≥65                  | 69 (36.7)  | 65.7          |         |
| Sex                  |         |                |         |
| Female               | 106 (56.4) | 81.4          | .159    |
| Male                 | 82 (43.6)  | 66.8          |         |
| Smoking              |         |                | .012    |
| Never                | 117 (62.2) | 82.7          |         |
| Ever                 | 71 (37.6)  | 61.0          |         |
| Nuclear atypia       |         |                | <.001   |
| Mild                 | 105 (55.9) | 90.2          |         |
| Moderate             | 59 (31.4)  | 60.5          |         |
| Severe               | 24 (12.8)  | 47.2          |         |
| Micropapillary       |         |                | <.001   |
| 0%                   | 128 (68.1) | 88.0          |         |
| 1%–9%                | 25 (13.3)  | 68.3          |         |
| ≥10%                 | 35 (18.6)  | 34.0          |         |
| Aerogenous spread    |         |                | <.001   |
| Absent               | 136 (72.3) | 84.0          |         |
| Present              | 52 (27.7)  | 53.2          |         |
| Vascular invasion    |         |                | <.001   |
| Absent               | 172 (91.5) | 79.5          |         |
| Present              | 16 (8.5)   | 24.9          |         |
| Necrosis             |         |                | <.001   |
| Absent               | 170 (90.4) | 79.4          |         |
| Present              | 18 (9.6)   | 32.2          |         |
| Neutrophils          |         |                | <.001   |
| Absent               | 118 (62.8) | 86.9          |         |
| Present              | 70 (37.2)  | 55.9          |         |
| Pleural status       |         |                | <.001   |
| PL0                  | 175 (93.1) | 79.6          |         |
| PL1–3                | 13 (6.9)   | 0.0*          |         |
| KRAS                 |         |                | .076    |
| Wild                 | 34 (57.6)  | 30.0          |         |
| Mutated              | 25 (42.4)  | 24.7          |         |
| N stage              |         |                | <.001   |
| 0                    | 177 (94.1) | 78.3          |         |
| 1/2                  | 11 (5.9)   | 18.5*         |         |
| T stage              |         |                | <.001   |
| 1a                   | 61 (32.4)  | 100.0         |         |
| 1b                   | 42 (22.3)  | 89.6          |         |
| 2a                   | 49 (26.1)  | 62.7          |         |
| 2b                   | 18 (9.6)   | 51.0          |         |
| 3/4                  | 18 (9.6)   | 23.4          |         |

DFS, disease-free survival; aTis, no invasion; aT1mi, minimal (<5 mm) invasion; aT1a1, >5 mm, ≤1 cm invasion; aT1a2, >1 cm, ≤2 cm invasion; aT1b, >2 cm, ≤3 cm invasion; aT2a, >3 cm, ≤5 cm invasion or visceral pleural invasion (PL1–2); aT2b, >5 cm, ≤7 cm invasion; aT3, >7 cm invasion or satellite tumor nodule in same lobe or parietal pleural invasion (PL3); aT4, satellite tumor nodule in different ipsilateral lobe. a,b,c All patients were censored at 47-, 53-, and 32-month follow-up, respectively.
RESULTS

Clinicopathologic characteristics

The clinicopathologic features are summarized in Table 1. The mean age was 59.9 years (range, 19 to 84 years), and 63.3% of patients were younger than 65 years. Female patients (56.4%) outnumbered male patients, and never smokers comprised 62.2% of all patients. Fifteen patients (8.0%) underwent wedge resection, one patient underwent segmentectomy, and 172 patients (91.5%) underwent at least lobectomy. Adjuvant chemotherapy was administered in 28 patients (14.9%), of which, eight were American Joint Committee on Cancer stage I, 16 were stage II, and four were stage III.

Mean tumor size was 3.6 cm (median, 2.8 cm; range, 0.5 to 20.0 cm). Nuclear atypia was mild in 105 (55.9%), moderate in 59 (31.4%), and severe in 24 (12.8%) cases. Micropapillary pattern was absent in 128 (68.1%), focally (1%–9%) present in 25 (13.3%), and substantially (≥10%) present in 35 (18.6%) cases. AS was present in 52 (27.7%) cases, which presented as lepidic, micropapillary, and both types in 34, 14, and four cases, respectively. Vascular invasion was present in 16 cases (8.5%). Necrosis and intra-alveolar neutrophil accumulation were present in 18 (9.6%) and 70 (37.2%) cases, respectively. Pleural invasion was present in 13 cases (6.9%). Nodal metastasis was present in 11 cases (5.9%).

Proportion of invasive patterns and distribution of aT stage

In all 188 patients, the mean proportion of invasive patterns was 21.4% (pattern 2, 13.0%; pattern 3, 8.4%), and the mean size of invasive patterns was 1.3 cm (median, 0.4 cm; range, 0.0 to 14.0 cm). In 49 cases (26.1%), the tumors were exclusively composed of non-invasive patterns (lepidic and pattern 1), and nine had a central scar. Among 49 non-invasive cases, nine showed a purely lepidic pattern, and 40 showed a mixture of lepidic and pattern 1. The proportion of invasive patterns increased in correlation with increased tumor size. The mean proportion of invasive pattern was 8.4% (pattern 2, 5.9%; pattern 3, 2.5%) in small (≤3 cm) tumors, 34.3% (pattern 2, 21.2%; pattern 3, 13.1%) in intermediate-sized (>3 cm and ≤7 cm) tumors, and 50.1% (pattern 2, 27.0%; pattern 3, 23.1%) in large (>7 cm) tumors. Accordingly, as shown in Table 1, 57 of 61 T1a cases (93.4%) and 29 of 42 T1b cases (69.0%) were adjusted to aTis/1mi, whereas only two of 18 T3/4 cases (11.1%) were adjusted to aTis/1mi. In other words, the 112 cases of aTis/1mi were generally small (≤3 cm, T1) tumors (86 cases, 76.8%), although intermediate-sized (>3 cm and ≤7 cm, T2) tumors (24 cases, 21.4%), and even large (>7 cm, T3) tumors (two cases, 1.8%) were also observed.

Fig. 3. Disease-free survival according to T stage (A) and adjusted T stage (B). aTis, no invasion; aT1mi, minimal (≤5 mm) invasion; aT1a1, >5 mm, ≤1 cm invasion; aT1a2, >1 cm, ≤2 cm invasion; aT1b, >2 cm, ≤3 cm invasion; aT2a, >3 cm, ≤5 cm invasion or visceral pleural invasion (PL1–2); aT2b, >5 cm, ≤7 cm invasion; aT3, >7 cm invasion or satellite tumor nodule in the same lobe or parietal pleural invasion (PL3); aT4, satellite tumor nodule in a different ipsilateral lobe.
Correlation of clinicopathologic features with aT stage and predominant invasive pattern

Clinicopathologic features according to aT stage are summarized in Table 1. Advanced aT stage was significantly associated with older age, male sex, and ever smokers (p = .004, p = .003, and p < .001, respectively). Tumors with advanced aT stage had significantly more nuclear atypia, micropapillary pattern, AS, vascular invasion, necrosis, neutrophils, nodal metastasis, and KRAS mutation (all p < .001, except for KRAS mutation p = .014). Significant associations between T stage and clinicopathologic features were similarly noted, with the exception of age (p = .101). To further evaluate the clinicopathologic relevance of a predominant invasive pattern, 85 cases with ≥10% invasive patterns were separated into two groups according to the predominant invasive pattern: 59 pattern 2 predominant tumors (69.4%) and 26 pattern 3 predominant tumors (30.6%). Among clinical and pathologic factors, only micropapillary pattern and AS were significantly prevalent in pattern 3 predominant tumors (both p < .001). The two groups showed no significant difference in DFS and extrathoracic recurrence-free survival, when they were

Fig. 4. Disease-free survival in separate T stage subgroups according to the adjusted T stage (A, C, E) and grouped adjusted T stage (B, D, F). (A, B) T1b subgroups (n = 42). (C, D) T2a subgroups (n = 49). (Continued to the next page)
compared in matched aT stage (data not shown).

**KRAS and EGFR mutation**

KRAS mutations were detected in 25 of 59 cases tested (42.4%). Most mutations were found in codon 12, with one case each of codon 13 (G13D) and codon 61 (Q61H) mutation. Among 23 cases of codon 12 mutations, the G12V mutation was most common (11 cases), followed by G12D (seven cases), G12C (four cases), and G12A (one case).

KRAS mutation was significantly less prevalent in low aT stage (25.8%, 75.0%, and 55.0% in aT0/1mi, aT1a/b, and aT2a/b, respectively; \( p = .014 \)). KRAS mutations showed no significant association with clinical factors including age, sex, and smoking status (all \( p > .5 \)). Among histologic factors, only neutrophil accumulation was significantly associated with KRAS mutations (\( p = .014 \)). EGFR mutation was detected in one of 68 cases tested; the single case was a male smoker with an exon 19 deletion, an invasive pattern greater than 5 mm, and recurrent disease. None of the cases showed concomitant KRAS and EGFR mutations.

**Prognostic impact of invasion size**

Thirty-six patients (19.1%) had recurrence or died of disease during follow-up. Extrathoracic recurrence was present in 11 patients (5.9%). None of the 16 patients who underwent sublobar resection experienced recurrence; all had small (≤2 cm) tumors, with 8 mm invasion in one case, ≤5 mm invasion in three cases, and no invasion in 12 cases. The median follow-up for patients without recurrence was 43.5 months (range, 0.5 to 184 months). DFS at 5 years for all 188 patients was 75.6%.

As shown in Table 2 and Fig. 3, DFS was significantly associated with T stage (overall \( p < .001 \)). Patients with small tumors (≤2 cm, T1a) had 5-year DFS of 100%. Patients with T1b, T2a, T2b, and T3/4 tumors had a 5-year DFS of 89.6%, 62.7%, 51.0%, and 23.4%, respectively. DFS was also significantly associated with aT stage (overall \( p < .001 \)). Forty-nine cases without invasion (aTis), including nine cases of pure lepidic growth, had no recurrence. In 63 cases with minimal invasion (≤5 mm invasion, aT1mi), 5-year DFS was 95.2%. Of these, tumor size was greater than 3 cm in 23 cases, and two of these cases experienced recurrence. These two cases were grossly 3.5-cm- and 4.5-cm-sized tumors, with 5 mm invasion for both. One case had minute (≤5%) micropapillary pattern foci, and both cases had no other adverse histologic features. Recurrence was not observed in 40 aT1mi cases with ≤3 cm, including five cases with AS, all of which were of lepidic type. Patients with aT1a1, aT1a2, aT1b, aT2a, and aT2b/3/4 stage had 5-year DFS of 75.3%, 54.1%, 41.7%, 20.3%, and 16.8% at 2.7 years, respectively.

aT stage was also a T stage–independent predictor of recurrence when patient survival within the separate T stage subgroups was assessed according to aT stage (Fig. 4). In the T1b subgroup, a significant difference in survival was observed between aTis/1mi group and aT1a/b group (5-year DFS, 100% and 68.6% for
Invasive Patterns in Mucinous Adenocarcinoma

\[ aTis/1mi \ (n = 29) \text{ and } aT1a/b \ (n = 13), \text{ respectively; } p = .008. \]

In the T2a subgroup, survival was also significantly stratified by aT stage (5-year DFS, 86.1%, 54.0%, and 0% at 3.9 years for aTis/1mi \( n = 21 \), aT1a/b \( n = 18 \) and aT2a/b \( n = 10 \), respectively; \( p = .002 \)). In the T2b subgroup, cases with advanced aT stage had a tendency for worse survival (5-year DFS, 100%, 60.0%, and 25.9% for aTis/1mi \( n = 3 \), aT1a/b \( n = 5 \), and aT2a/b \( n = 10 \), respectively; \( p = .071 \)). Conversely, survival within the separate aT stage was not relevant to T stage (Fig. 5).

Univariate analyses of clinicopathologic variables are summarized in Table 2. Smokers had significantly worse DFS (\( p = .012 \)). Patients with older age and male sex had worse DFS, although this was not statistically significant (\( p = .097 \) and \( p = .159 \), respectively). KRAS mutation showed no significant associations with survival (\( p = .076 \)). Nuclear atypia, micropapillary pattern, AS, vascular invasion, and intra-alveolar neutrophils were all associated with worse DFS (all \( p < .001 \)). Pleural invasion and nodal metastasis were also associated with worse DFS (both \( p < .001 \)).

In multivariate analysis (Table 3), invasion size retained a significant association with DFS (hazard ratio [HR], 5.57; 95%
confident results.

### DISCUSSION

In our largest series of pulmonary mucinous adenocarcinomas to date, we have shown that the prognosis of mucinous adenocarcinoma is largely determined by the size of invasive patterns. Although conventional tumor staging by total size was associated with prognosis, tumors within the separate T stage subgroups showed heterogeneous proportions of invasive growth patterns, which were correlated with patient outcome. Our results indicate that the size of invasive patterns may have greater prognostic impact than gross size in mucinous adenocarcinomas.

We also demonstrated that advanced aT stage and T stage tumors were significantly associated with adverse histologic features and clinical features including older age, male sex, and smoking. Notably, low-stage tumors in our cohort had a significantly lower rate of KRAS mutation, whereas intermediate- and high-stage tumors showed a mutation rate comparable to that in previous studies.\(^4\,24\,25\) This unexpectedly low rate of KRAS mutation in low-stage, non-invasive mucinous adenocarcinomas was first described by Sato et al.\(^26\) However, others with a larger number of cases have shown that KRAS mutation status is irrelevant to stage.\(^4\,24\) Future studies with data on genetic background in low-stage tumors are needed to support either concept.

In previous studies, mucinous adenocarcinoma accounted for 2%–5% of resected lung adenocarcinomas, which was comparable to 4.6% in our cohort.\(^2\,10\,27\) The true prognosis of mucinous adenocarcinomas is puzzling, and they are often regarded as aggressive, multicentric, unresectable tumors with dismal prognosis.\(^28\) For resectable cases, however, the most recent study by Shim et al.\(^4\) of 83 mucinous adenocarcinomas based on a Korean and American population showed that recurrence-free survival was not inferior to that of non-mucinous tumors. In addition, absence of extrapulmonary recurrence was documented in their study. Ichinokawa et al.\(^27\) also reported that, in their series of 13 mucinous adenocarcinomas predominantly composed of goblet cells had 95.7% 5-year DFS and absence of nodal metastasis, although they might have excluded cases showing substantial stromal invasion, which generally have altered cytomorphologic features, since an inclusion criterion of ≥90% goblet cell component was employed in their study. Oka et al.\(^29\) reported that, in their series of 13 mucinous adenocarcinomas, eight patients with tumors ≤3 cm had no recurrence. Our data showed results consistent with those from the abovementioned studies in that lymph node metastasis and extrathoracic recurrence rarely occurred in mucinous adenocarcinoma, and small tumors generally showed excellent prognosis. Several studies validating the prognostic impact of the 2011 IASLC/ATS/ERS classification also included cases of mucinous adenocarcinomas. However, due to the rarity of this tumor, only limited numbers were enrolled, and these studies yielded conflicting results.\(^2\,10\) We think the limited number of mucinous adenocarcinomas which lack representativeness might have resulted in the varied results observed in these studies. Furthermore, we think it may be misleading to generalize the prognosis of mucin-
nous adenocarcinomas by comparing them as a whole with other non-mucinous adenocarcinomas showing different architectural patterns, since this could disregard the importance of different stages and invasive growth patterns within mucinous adenocarcinoma, which have significant prognostic impact.

Our study is the first to describe the prevalence, prognostic impact, and the criteria of invasive patterns in mucinous adenocarcinoma. Histologic criteria for invasion in lung adenocarcinomas have evolved for over a decade. However, no study has yet focused on invasion criteria for mucinous adenocarcinoma. In a review of the literature, the presence of a central scar or back-to-back glands was regarded as a feature of invasion. Interestingly, some pathologists seem to interpret a mucinous lepidic pattern itself as invasion based on the assumption that there will be an invasion in the other area of tumor. According to our data, we believe it is reasonable not to interpret lepidic pattern or non-distorted acini (pattern 1)—even when they are compactly arranged or embedded in a central scar—as an invasive pattern, since these acini can also represent pre-existing alveolar spaces lined by tumor cells, which are still, by definition, a lepidic pattern. Furthermore, none of the cases exclusively composed of pattern 1 and lepidic pattern showed recurrence, and adjustment for tumor stage by subtracting these components has led to more precise prediction of patient outcomes. Thus, we suggest that pattern 1 is a morphologic spectrum of the lepidic pattern, or at least a pattern that is related to indolent biologic behavior as a lepidic pattern. On the other hand, by using the invasion criteria proposed in this study, as many as 81 of 188 cases in our cohort (43.1%) would be categorized as “adenocarcinoma in situ” or “minimally invasive adenocarcinoma” according to the current WHO classification criteria, showing ≤ 5-cm tumors with ≤ 5-mm invasion and no other adverse histologic features such as AS. Although this incidence is surprisingly high, none of the cases presented with recurrence, showing that these conceptual diagnostic categories are still valid when our invasion criteria are used.

Our results represent a Korean population from a single institution, and our findings need to be confirmed in further studies with a sufficient number of cases representing other ethnicities. Furthermore, histologic criteria applied in the present study may exhibit interobserver variability, similar to growth pattern analysis for conventional adenocarcinomas. Through our histologic review, distinguishing destroyed alveolar spaces from distended alveolar spaces and intra-alveolar proliferation from a lepidic pattern with mild serration was often difficult.

In summary, we showed that the size of invasive patterns determined using the histologic criteria proposed in this study predicts recurrence in pulmonary mucinous adenocarcinomas. Risk stratification relying solely on total size may have pitfalls, since tumors show diverse outcomes that are dependent on the size of the invasive pattern. We expect our data to provide guidance regarding the treatment of this distinct variant of lung adenocarcinoma.

Conflicts of Interest
No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
2. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press, 2015.
3. Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer 2008; 9: 24-9.
4. Shim HS, Kerudson N, Zheng Z, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the Lung. J Thorac Oncol 2015; 10: 1156-62.
5. Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 2014; 4: 415-22.
6. Nakaoku T, Tsuta K, Ichikawa H, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res 2014; 20: 3087-93.
7. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-504.
8. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24: 653-64.
9. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
10. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013; 8: 52-61.

11. Kadota K, Villena-Vargas J, Yoshizawa A, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 2014; 38: 448-60.

12. Takahashi Y, Ishii G, Aokage K, Hishida T, Yoshida J, Nagai K. Distinctive histopathological features of lepidic growth predominant node-negative adenocarcinomas 3-5 cm in size. Lung Cancer 2013; 79: 118-24.

13. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 2004; 28: 198-206.

14. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009; 33: 462-9.

15. Nishino M, Klepsis VE, Yeap BY, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 2012; 25: 1462-72.

16. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011; 35: 1226-34.

17. Fukutom T, Hayashi Y, Emoto K, Komiya K, Kohno M, Sakamoto M. Low papillary structure in lepidic growth component of lung adenocarcinoma: a unique histologic hallmark of aggressive behavior. Hum Pathol 2013; 44: 1849-58.

18. Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK. AJCC cancer staging atlas: a companion to the seventh editions of the AJCC cancer staging manual and handbook. New York: Springer-Verlag, 2012.

19. Warth A, Muley T, Kossakowski CA, et al. Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma. Am J Surg Pathol 2015; 39: 799-801.

20. Kadota K, Nitadori J, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. J Thorac Oncol 2015; 10: 806-14.

21. Bellocq A, Antoine M, Flahault A, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998; 152: 83-92.

22. Wislez M, Massiani MA, Mller B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest 2003; 123: 1868-77.

23. Sun JM, Lira M, Pandya K, et al. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer 2014; 83: 259-64.

24. Ichinokawa H, Ishii G, Nagai K, et al. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Hum Pathol 2013; 44: 2636-42.

25. Kakegawa S, Shimizu K, Sugano M, et al. Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer 2011; 117: 4257-66.

26. Sato S, Motoi N, Hiramatsu M, et al. Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. Am J Surg Pathol 2015; 39: 912-21.

27. Ichinokawa H, Ishii G, Nagai K, et al. Clinicopathological characteristics of primary lung adenocarcinoma predominantly composed of goblet cells in surgically resected cases. Pathol Int 2011; 61: 423-9.

28. Manning JT Jr, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma: the significance of two histopathologic types. Cancer 1984; 54: 525-34.

29. Oka S, Hanagiri T, Uramoto H, et al. Surgical resection for patients with mucinous bronchioloalveolar carcinoma. Asian J Surg 2010; 33: 89-93.

30. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000; 69: 893-7.

31. Borczuk AC. Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Mod Pathol 2012; 25 Suppl 1: S1-10.

32. Thurisn E, Beasley MB, Borczuk AC, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma: an international interobserver study. Mod Pathol 2012; 25: 1574-83.

33. Warth A, Stenzinger A, von Brünneck AC, et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. Eur Respir J 2012; 40: 1221-7.